Skip to main content

Show 20 results Show all

Self-injected subcutaneous DMPA: A new frontier in advancing contraceptive access and use for women

This brief details the strong body of evidence and experience with self-injection of DMPA-SC in low-resource settings, including how the practice can reduce access-related barriers, improve contraceptive continuation, and enhance women’s autonomy.

Institutional Author(s): PATH
Publication date: October, 2019

Resources: A list of references about subcutaneous DMPA

This brief lists key references and resources from the evidence base on DMPA-SC. Pair this with the Evidence at-a-glance brief if your target decision-maker would like to have access to the data in that handout.

Institutional Author(s): PATH
Publication date: October, 2019

An overview of subcutaneous DMPA: A new type of injectable contraception that expands access and options

This brief offers quick facts on the benefits of DMPA-SC; the product’s potential for empowering women and adolescent girls; the product’s availability; and how subcutaneous DMPA is different from intramuscular DMPA (DMPA-IM).

Institutional Author(s): PATH
Publication date: October, 2019

Advocacy pack for subcutaneous DMPA: Tools for advocacy and communications to increase access to a new type of injectable contraception

Subcutaneous DMPA (DMPA-SC) is an innovative and easy-to-use injectable that is transforming contraceptive access, use, and choice for women and adolescent girls. Advocates have an important role to play in making sure their country’s policies and funding support access to a broad method mix, including new options like DMPA-SC.

The Advocacy Pack for Subcutaneous DMPA is designed to accelerate your advocacy efforts. It consists of evidence-based materials, in English and French, for advocates to use both for their own strategy development and for direct advocacy with decision-makers. Materials are customizable and unbranded so that you can tailor them to your country context.

Institutional Author(s): PATH
Publication date: October, 2019

Expanding Access to Injectable Contraceptives through Pharmacies Toolkit

This toolkit contains resources designed to help pharmacy associations become effective advocates and begin working to change policies in their countries. The toolkit can be adapted to advocate for any injectable contraceptive. The toolkit includes a Resource for Considering DMPA-SC.

Institutional Author(s): SHOPS Plus, USAID
Publication date: May, 2019

Tool Web page

Messaging points on subcutaneous DMPA

This brief packages accurate, evidence-based messages about the features and benefits of DMPA-SC and how the product can increase women’s access to contraception.

Institutional Author(s): PATH
Publication date: October, 2019

Tips for engaging traditional and social media for advocacy on subcutaneous DMPA

This brief provides tips on when, why, and how to engage traditional and social media to advance your advocacy to increase access to DMPA-SC.

Institutional Author(s): PATH
Publication date: October, 2019

Evidence at-a-glance: What we know about subcutaneous DMPA, a new type of injectable contraception

This brief outlines existing evidence on DMPA-SC with data grouped into top-line, evidence-based messages, with corresponding data from different countries. This handout can be printed and distributed directly to decision-makers. It contains several one-page spotlight handouts on specific sub-topics, which can be printed and paired with the two-page summary—for distribution to decision-makers—as needed.

Institutional Author(s): PATH
Publication date: October, 2019

The case for subcutaneous DMPA

Using simple messages, this case statement describes reasons why DMPA-SC is a valuable and game-changing addition to a broad contraceptive method mix.

Institutional Author(s): PATH
Publication date: October, 2019

Costs and cost-effectiveness of subcutaneous DMPA through different delivery channels: What new evidence tells us

This brief summarizes recent evidence from African countries on the costs and cost-effectiveness of DMPA-SC. Key findings include that DMPA-SC may help reduce service delivery costs by catalyzing expansion of channels closest to women and that self-injected DMPA-SC is cost-saving as compared to clinic-administered DMPA-IM when accounting for costs to women and health systems.

Institutional Author(s): PATH
Publication date: October, 2019